[
Skip to content
]
Text Only
|
Site map
|
Text size:
big
/
normal
/
small
Find information
Visit one of our cancer information centres
Select A Cancer
-----------
Anal Cancer
Bladder Cancer
Bone Tumours
Brain Tumours
Breast Cancer
Cancer Of The Cervix
-----------
Cancer Of The Pancreas
Colon And Rectal Cancer
Head And Neck Cancer
Hepatocellular Carcinoma
Hodgkin's Disease
Kidney Cancer
-----------
Lung Cancer
Melanoma
Myeloma And Plasmacytoma
Non Hodgkin's Lymphoma
Oesophageal Cancer
Ovarian Cancer
-----------
Prostate Cancer
Soft Tissue Sarcomas
Stomach Cancer (Gastric Cancer)
Testis Cancer
Thyroid Cancer
Uterine Cancer
Search the site
In this section...
Pegylated Liposomal Doxorubicin
Trial on chemotherapy in bladder cancer
Therapy delivers toxin to glioblastoma cells
Raloxifene and breast cancer prevention
Letrozole approved for use after Tamoxifen
Nanoparticle Taxol (paclitaxel) is better
Neoadjuvant Anastrazole conservation
Gene expression profiling predicts prognosis
Oral Ibandronate reduces metastases
Should Adjuvant Tamoxifen be delayed
Taxane based chemo improves survival
Risk reducing Salpingo-oophorectomy
Tamoxifen may have a rival: Anastrazole
Aromatase inhibitors better than Tamoxifen
Combined Tamoxifen and Ovarian Ablation
Oestrogen Receptor Expression, Tamoxifen etc
Breast conserving surgery and Brca-linked
Humanised Monoclonal Antibody; Her-2 receptor
Capecitabine plus Taxotere; metastatic cancer
Taxol plus Adriamycin chemotherapy
The effect of age on overall prognosis
Herceptin plus chemotherapy
Adjuvant Systemic therapy
Adjuvant Radiotherapy in conserved breasts
Discovery of Cytokeratin positive cells
Anastrozole as effective as Tamoxifen?
Scar-free breast reconstruction technique
Fluoxetine reduces hot flashes
High dose chemotherapy and Autologous Re-infu
Gardasil Hpv (human Papilloma Virus) vaccine
Racial differences in the outcome of therapy
Synchronous chemo- and radio-therapy
Erlotinib prolongs survival
Gemcitabine plus Irinotecan chemotherapy
Osi-774 therapy in advanced squamous cancer
Cancer of the pharynx and radiotherapy
Amifostine protects salivation in irradiated
Positron emission tomography (pet) scannining
Second tumours in head and neck cancer
Cisplatinum adds to standard radiotherapy
Very accelerated radiotherapy
Radiotherapy and concurrent Cis-platinum
Hepatitis B Vaccine
Cis-platin gel injection
Sunitinib therapy in kidney cancer
Nephrectomy followed by Interferon
High dose Interleukin-2 (hd Il-2)
Lung cancer screening by CT
Erlotinib improves the survival of patients
Combination chemotherapy beats single agents
Genetic link to malignant Mesothelioma
Docetaxel in locally advanced lung cancer
Radiotherapy and Tewo drug chemotherapy
Prophylactic Cranial Radiotherapy
Etoposide/platinum chemotherapy
Amifostine as a Radio- and Chemo- Protector
Positron Emission Tomography (PET)
Antisense agent improves response rate
Prognostic factors in melanoma patients
High dose Interferon: Antigen Gm-2
Adding to Interferon does not improve results
PET scanning for detecting metastatic melanom
Temozolamide in chemotherapy
Morton tones down his opinion on vaccine
Randomised trial of chemotherapy
Sentinal node biopsy: value of tumour burden
New American joint committee staging system
Tumour vaccine therapy
Bortezomib in myeloma
Thalidomide as first therapy for myeloma
Chemotherapy prior to surgery
Chemo-radiotherapy for oesophageal cancer
Novel Glutathione leads to longer remission
Brca gene mutations and survival
Pegylated Liposomal Doxorubicin vs Topotecan
Glutamine may reduce severity of Paclitaxel
Aspirin may lower the risk of ovarian cancer
Intraperitoneal radio-immunotherapy
Salvage chemotherapy: ralpsed ovarian cancer
Platinum/taxol chemotherapy is best
Salvage radiotherapy in radical prostatectomy
Maximum androgen blockade in advanced cancer
Salvage brachytherapy
The problem of the rising PSA
Refining PSA as a serum marker for diagnosis
Intermittent anti-androgen therapy
Long term hormones beneficial
Sexual potency after treatment
Atrasentin, an Endothelin A (et-a) receptor
High tissue inhibitor of metalloproteinases
Finasteride/proscar
Toremifene may lower the risk of PIN
Permanent radio-isotope brachytherapy
Selection of patients for prostate biopsy
PSA velocity prior to prostatectomy
Post-operative radiotherapy in T3 disease
Who should receive adjuvant chemotherapy?
High dose Melphalan and autologous transplant
PET scanning helps stage and grade sarcomas
Localised limb osteosarcoma
The use of neoadjuvant chemotherapy
Iphosphamide, Carboplatin and Etoposide
ST1571 in gastrointestinal stromal tumours
Topoisomerase 1 inhibitors activity
Hereditary stomach cancer
Heliobacter infection
Testicular lymphoma and relapse sites
Iodine-123 better for imaging than iodine-131
More rapid assays of Serum Thyroglobulin
Thalidomide therapy in advanced cancer
Satraplatin slows prostate cancer progression
Sorafenib gives new hope for liver cancer
Axitinib gives new hope for thyroid cancer
On this site...
Home
Cancer information
Expert advice
Specialists
Cancer centres
Support groups
Current issues
Cancer news
Recommended books
Glossary
About us
Home
→
Current issues
→
Pegylated Liposomal Doxorubicin
.
Pegylated Liposomal Doxorubicin in refractory sarcoma chemotherapy
Doxorubicin is the best established chemotherapy agent in sarcoma therapy. The relatively newly liposomal formulation of the compound has been shown to have similar activity against the cancer but a better toxicity profile.
